TransMedics reported Q4 2025 total revenue of USD 160.8 million (+32%) and FY 2025 total revenue of USD 605.5 million (+37%). Q4 2025 gross margin was 58% and FY 2025 gross margin was 60%. Q4 2025 operating expenses were USD 72.1 million and FY 2025 operating expenses were USD 254.2 million. Q4 2025 net income was USD 105.4 million (USD 2.62 diluted EPS), including a net income tax benefit of USD 83.8 million primarily tied to the release of a valuation allowance related to deferred tax assets; FY 2025 net income was USD 190.3 million (USD 4.87 diluted EPS), including a net income tax benefit of USD 82.8 million. For operations, TransMedics completed 5,139 U.S. OCS cases in FY 2025 (+38%) and ended 2025 with 22 owned aircraft. The company also highlighted FDA approval for the OCS ENHANCE Heart and DENOVO Lung trials, a long-term lease for a new global headquarters at Assembly Innovation Park in Somerville, Massachusetts with adjacent land acquisition for an integrated campus, and several leadership appointments (including a new Chief Commercial Officer effective February 2, 2026). TransMedics guided FY 2026 revenue to USD 727 million to USD 757 million (+20% to +25%).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241605PR_NEWS_USPR_____NE94786) on February 24, 2026, and is solely responsible for the information contained therein.